A review of cost–effectiveness of palivizumab for respiratory syncytial virus
Author:
Publisher
Informa UK Limited
Subject
Pharmacology (medical),Health Policy,General Medicine
Link
http://www.tandfonline.com/doi/pdf/10.1586/erp.12.45
Reference86 articles.
1. The Burden of Respiratory Syncytial Virus Infection in Young Children
2. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis
3. An evaluation of the emerging interventions against Respiratory Syncytial Virus (RSV)-associated acute lower respiratory infections in children
4. Revised Indications for the Use of Palivizumab and Respiratory Syncytial Virus Immune Globulin Intravenous for the Prevention of Respiratory Syncytial Virus Infections
Cited by 19 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Breakthrough therapy designation of nirsevimab for the prevention of lower respiratory tract illness caused by respiratory syncytial virus infections (RSV);Expert Opinion on Investigational Drugs;2021-12-28
2. Antibody and Local Cytokine Response to Respiratory Syncytial Virus Infection in Community-Dwelling Older Adults;mSphere;2020-10-28
3. Cost-effectiveness of Palivizumab for Respiratory Syncytial Virus: A Systematic Review;Pediatrics;2019-05-01
4. Healthcare resource use and economic burden attributable to respiratory syncytial virus in the United States: a claims database analysis;BMC Health Services Research;2018-04-20
5. Common Queries About Immunizations in Preterm Infants;Pediatric Annals;2018-04
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3